HOLX - Hologic, Inc.
| Previous Close | 45.07 |
| Open | 44.75 |
| Bid | 44.89 x 2900 |
| Ask | 45.49 x 800 |
| Day's Range | 44.75 - 45.29 |
| 52 Week Range | 37.47 - 48.82 |
| Volume | 1,138,574 |
| Avg. Volume | 1,626,063 |
| Market Cap | 12.027B |
| Beta (3Y Monthly) | 0.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GuruFocus.com•11 days agoKahn Brothers Trims New York Times, Hologic Positions
Founded in 1978, Kahn Brothers (Trades, Portfolio) & Co. Inc. currently manages more than $800 million in assets. Warning! GuruFocus has detected 3 Warning Sign with BOM:532772. The trade had an impact of -2.24% on the portfolio.
- Markit•12 days ago
See what the IHS Markit Score report has to say about Hologic Inc.
Hologic Inc NASDAQ/NGS:HOLXView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for HOLX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding HOLX totaled $8.24 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Thomson Reuters StreetEvents•16 days ago
Edited Transcript of HOLX earnings conference call or presentation 1-May-19 8:30pm GMT
Q2 2019 Hologic Inc Earnings Call
- CNBC•17 days ago
Cramer Remix: Why buybacks have not benefited Bed Bath & Beyond
Jim Cramer explains how the retailer has hurt itself by spending fortunes buying back stock.
- Zacks•17 days ago
Hologic's (HOLX) Q2 Earnings Beat Estimates, Margins Fall
Hologic (HOLX) registers solid Q1year-over-year revenue growth in core businesses like Breast Health and Molecular Diagnostics.
Motley Fool•18 days agoHologic Inc (HOLX) Q2 2019 Earnings Call Transcript
HOLX earnings call for the period ending March 30, 2019.
- Zacks•18 days ago
Hologic (HOLX) Beats Q2 Earnings and Revenue Estimates
Hologic (HOLX) delivered earnings and revenue surprises of 1.75% and 1.59%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•18 days ago
Hologic: Fiscal 2Q Earnings Snapshot
On a per-share basis, the Marlborough, Massachusetts-based company said it had a loss of $1.01. Earnings, adjusted for non-recurring costs, came to 58 cents per share. The results beat Wall Street expectations. ...
- Benzinga•18 days ago
Hologic's Q2 Earnings Preview
Hologic (NASDAQ: HOLX ) releases its next round of earnings this Wednesday, May 1. Here's Benzinga's essential guide to Hologic's second-quarter earnings report. Earnings and Revenue Wall Street expects ...
- Zacks•25 days ago
Hologic (HOLX) Earnings Expected to Grow: Should You Buy?
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Simply Wall St.•last month
How Financially Strong Is Hologic, Inc. (NASDAQ:HOLX)?
Hologic, Inc. (NASDAQ:HOLX), a large-cap worth US$13b, comes to mind for investors seeking a strong and reliable stock investment. One reason being its ‘too big to fail’ aura which gives it the appearance of a strong and stable inv...
- Investopedia•last month
Double Top Spells Trouble for 3 Health Care Stocks
Health care stocks have fallen out of favor due to sector rotation and political pressure. Explore three trading ideas to benefit from falling prices.
- Zacks•last month
Hologic's Diagnostics Grows Strong, Escalating Costs a Woe
To fortify its product portfolio, Hologic (HOLX) is working on innovations and product introductions. On this front, Cynosure's R&D pipeline stays robust.
- Insider Monkey•last month
Were Hedge Funds Right About Flocking Into Hologic, Inc. (HOLX)?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
- Zacks•2 months ago
Here's Why You Should Invest in ResMed (RMD) Stock Right Now
ResMed (RMD) continues to invest and expand presence in high-growth markets like China, South Korea, India, Brazil and many countries in Eastern Europe.
- Zacks•2 months ago
Genomic Health's New Positive Data to Boost Test Uptake
Genomic Health (GHDX) continues to see positive developments for Oncotype DX Breast Recurrence Score tests.
- Zacks•2 months ago
Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock
The innovation-based, multi-modality global strategy, enabled by enhanced commercial capability, accelerates IDEXX's (IDXX) recurring CAG Diagnostics revenue growth.
- Zacks•2 months ago
Neogen (NEOG) Earnings and Revenues Miss Estimates in Q3
Continued weakness in the global animal protein market and strongly negative currency conversions posed as headwinds for Neogen (NEOG) in third-quarter fiscal 2019.
- Zacks•2 months ago
Zimmer Biomet's FDA 510(k) Nod Widens Robotic Offerings
With the FDA nod, Zimmer Biomet (ZBH) attains the status of being the first company to boast the 510(k) clearance for Brain, Spine and Knee offerings on a single robotic platform globally.
- Zacks•2 months ago
Here's Why You Should Invest in Genomic Health (GHDX) Now
Having established a strong foothold in the U.S. market, Genomic Health (GHDX) is now making considerable expansion in the international arena.
- Zacks•2 months ago
Abbott's New CE Mark to Boost Core Laboratory Diagnostics Arm
Abbott's (ABT) Alinity m diagnostics system and assays will provide increased flexibility and time efficiency while catering to the rising demand for infectious disease testing.
- Zacks•2 months ago
National Vision (EYE) Rides on Positive Comps Amid Cost Woes
National Vision (EYE) has been witnessing positive comps owing to increased customer transaction over the last 68 sequential quarters.
- CNBC•17 days ago
Hologic CEO: Preventing false positives with 3D mammography technology
Hologic CEO Stephen MacMillan explains to Jim Cramer how the company is using technology to address challenges in women's health.
